scholarly journals Models of service delivery for optimizing a patient’s first six months on antiretroviral therapy for HIV: an applied research agenda

2020 ◽  
Vol 4 ◽  
pp. 116 ◽  
Author(s):  
Sydney Rosen ◽  
Anna Grimsrud ◽  
Peter Ehrenkranz ◽  
Ingrid Katz

Differentiated models of service delivery (DSD models) for HIV treatment in sub-Saharan Africa were conceived as a way to manage rapidly expanding populations of experienced patients who are clinically “stable” on antiretroviral therapy (ART). Entry requirements for most models include at least six months on treatment and a suppressed viral load. These models thus systematically exclude newly-initiated patients, who instead experience the conventional model of care, which requires frequent, multiple clinic visits that impose costs on both providers and patients. In this open letter, we argue that the conventional model of care for the first six months on ART is no longer adequate. The highest rates of treatment discontinuation are in the first six-month period after treatment initiation. Newly initiating patients are generally healthier than in the past, with higher CD4 counts, and antiretroviral medications are better tolerated, with fewer side effects and substitutions, making extra clinic visits unnecessary. Improvements in the treatment initiation process, such as same-day initiation, have not been followed by innovations in the early treatment period. Finally, the advent of COVID-19 has made it riskier to require multiple clinic visits. Research to develop differentiated models of care for the first six-month period is needed. Priorities include estimating the minimum number and type of provider interactions and ART education needed, optimizing the timing of a patient’s first viral load test, determining when lay providers can replace clinicians, ensuring that patients have sufficient but not burdensome access to support, and identifying ways to establish a habit of lifelong adherence.

2019 ◽  
Author(s):  
Samuel Kasozi ◽  
Nicholas Sebuliba Kirirabwa ◽  
Derrick Kimuli ◽  
Henry Luwaga ◽  
Enock Kizito ◽  
...  

Abstract Background Worldwide, Drug resistant Tuberculosis (DR-TB) remains a big problem; the diagnostic capacity has superseded the DR-TB clinical management capacity thereby causing ethical challenges. In Sub-Saharan Africa, treatment is either inadequate or lacking and some diagnosed patients are on treatment waiting lists. In Uganda, various health system challenges impeded scale up of DR-TB care in 2012; only three treatment initiation facilities existed, with only 41 of the estimated 1010 cases enrolled on treatment yet 300 were on the waiting list and there was no DR-TB treatment scale up plan. To scale up care, National TB/Leprosy Program (NTLP) with partners rolled out a DR-TB mixed model of care. In this paper, we share achievements and outcomes resulting from the implementation of this mixed Model of DR-TB care. Methods Routine NTLP DR-TB program data from 2013 to 2017 cohorts was collected from all the 15 DR-TB treatment initiation sites and analyzed using STATA version 14.2. We presented outcomes as the number of patient backlog cleared, DR-TB initiation sites, cumulative patients enrolled, percentage of co-infected patients on co-trimoxazole preventive therapy (CPT) and antiretroviral therapy (ART) as well as the six, twelve interim and 24 months treatment outcomes as per the Uganda NTLP 2016 Programmatic Management of drug Resistant Tuberculosis (PMDT) guidelines. Results Over the period 2013-2017, DR-TB treatment initiation sites increased from three to 15, cumulative patient enrollment rose from 41 to 1,311 and the 300-patient backlog was cleared. Treatment success rate (TSR) of 73% was achieved above the global TSR average rate of 50%. Conclusions The Uganda DR-TB mixed model of care coupled with early application of continuous improvement approaches, enhanced cohort reviews and use of multi-disciplinary teams allowed for rapid DR-TB program expansion, rapid clearance of patient backlog, attainment of high cumulative enrollment and high treatment success rates. Sustainability of these achievements is needed to further reduce the DR-TB burden in the country. We highly recommend this mixed model of care in settings with similar challenges.


Author(s):  
Saheed Opeyemi Usman ◽  
Adetosoye Adebanjo ◽  
Anuri Emeh ◽  
Ererosanaga Ogboghodo ◽  
Babatunde Akinbinu ◽  
...  

Background: In sub-Saharan Africa where genotypic drug resistance testing is rarely performed and poor adherence is blamed for the inability to achieve viral suppression and treatment failure, programmatic approaches to preventing & handling these are thus essential. Hypothesis tested was antiretroviral therapy adherence effect on viral load outcome. This study was aimed at determining and monitoring HIV/AIDS disease progression using viral load to provide prognostic information and evaluate patients for viral suppression using the World Health Organization (WHO) guideline strategies. Methods: This study was an observational study of subjects living with HIV already initiated on antiretroviral therapy for at least six months, enrolled in health facilities across Ondo State, South-Western Nigeria, during a 12-month observation period starting October 2018 till September 2019. Quantitative viral load analysis was done using Polymerase Chain Reaction, Roche Cobas Taqman 96 Analyzer. All data were statistically analyzed, using Statistical Package for the Social Sciences (SPSS), with multiple comparisons done using Post Hoc Bonferonni test. Results: A total of 8124 (1947 males & 6177 females) subjects eligible for the study were recruited. Most of them are in the age range of 35 – 39 years, with a mean age of 42.02 ± 10.88 years. 7162 (88.2%) & 1771 (21.8%) of the subjects had viral suppression of <1000 RNA copies per ml and <20 RNA copies per ml respectively. The unsuppressed subjects went through enhanced adherence counselling (EAC) for three months and viral load test repeated thereafter. 192 patients who had completed the three sessions of EAC and repeated viral load increased the entire suppression numbers to 7339 (90.3%) & 1824 (22.5%) <1000 RNA copies per ml and <20 RNA copies per ml respectively during the period of observation. ART adherence has significant effect on viral load outcome from the study hypothesis tested. Conclusion: Current ART regimen & HIV treatment enhanced adherence counseling are key to the achieving viral suppression, thus, routine viral load monitoring will ultimately help in HIV/AIDS disease progression follow up and reduce treatment failure tendencies. This will help more patients stay on first line regimen and prolong their life expectancy, indicating that the UNAIDS last 90 target is achievable.


AIDS ◽  
2014 ◽  
Vol 28 ◽  
pp. S73-S83 ◽  
Author(s):  
Ronald Scott Braithwaite ◽  
Kimberly A. Nucifora ◽  
Christopher Toohey ◽  
Jason Kessler ◽  
Lauren M. Uhler ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Francis Ateba Ndongo ◽  
Mathurin Cyrille Tejiokem ◽  
Calixte Ida Penda ◽  
Suzie Tetang Ndiang ◽  
Jean-Audrey Ndongo ◽  
...  

Abstract Background In most studies, the virological response is assessed during the first two years of antiretroviral treatment initiated in HIV-infected infants. However, early initiation of antiretroviral therapy exposes infants to very long-lasting treatment. Moreover, maintaining viral suppression in children is difficult. We aimed to assess the virologic response and mortality in HIV-infected children after five years of early initiated antiretroviral treatment (ART) and identify factors associated with virologic success in Cameroon. Methods In the ANRS-12140 Pediacam cohort study, 2008–2013, Cameroon, we included all the 149 children who were still alive after two years of early ART. Virologic response was assessed after 5 years of treatment. The probability of maintaining virologic success between two and five years of ART was estimated using Kaplan-Meier curve. The immune status and mortality were also studied at five years after ART initiation. Factors associated with a viral load < 400 copies/mL in children still alive at five years of ART were studied using logistic regressions. Results The viral load after five years of early ART was suppressed in 66.8% (60.1–73.5) of the 144 children still alive and in care. Among the children with viral suppression after two years of ART, the probability of maintaining viral suppression after five years of ART was 64.0% (54.0–74.0). The only factor associated with viral suppression after five years of ART was achievement of confirmed virological success within the first two years of ART (OR = 2.7 (1.1–6.8); p = 0.033). Conclusions The probability of maintaining viral suppression between two and five years of early initiated ART which was quite low highlights the difficulty of parents to administer drugs daily to their children in sub-Saharan Africa. It also stressed the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.


2021 ◽  
Vol 70 (21) ◽  
pp. 775-778
Author(s):  
Shirley Lee Lecher ◽  
Peter Fonjungo ◽  
Dennis Ellenberger ◽  
Christiane Adje Toure ◽  
George Alemnji ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2626-2626
Author(s):  
Satish Gopal ◽  
Yuri D. Fedoriw ◽  
Nathan Montgomery ◽  
Agnes Moses ◽  
Richard Nyasosela ◽  
...  

Abstract Introduction. There are scarce prospective data for lymphoma patients in sub-Saharan Africa since antiretroviral therapy (ART) scale-up began. We report early data from the Kamuzu Central Hospital (KCH) Lymphoma Study in Lilongwe,Malawi. KCH is the cancer referral center for Malawi’s northern and central regions. Methods. The KCH Lymphoma Study is a prospective observational cohort study initiated in June 2013. All diagnoses are pathologically confirmed using core biopsies or cell blocks from fine needle aspirates, supported by immunohistochemistry and weekly telepathology consultation between pathologists in Malawi and the US. Adult patients with confirmed lymphoma receive a comprehensive baseline evaluation including standardized staging. Patients undergo longitudinal follow-up with active tracing and transportation reimbursement to promote adherence to care. Response is assessed using standardized criteria incorporating physical exam, chest x-ray, and abdominal ultrasound. For these analyses, we focused on adults ≥18 years enrolled from June 1, 2013 until May 31, 2014. Chemotherapy protocols are standardized, and HIV+ patients receive ART concurrently with chemotherapy. Results. Seventeen of 38 (45%) of patients with lymphoma were HIV+. Baseline characteristics for HIV+ and HIV- patients were similar although HIV- patients presented with bulkier disease (median 10 vs 6 cm, p=0.027, Table 1). Among HIV+ patients, 82% were on ART for a median 22.5 months before lymphoma diagnosis (range 0.2-98.8). Median CD4 was 178 cells/µL and 53% had suppressed HIV RNA <400 copies/mL. Thirty-one patients were treated with first-line CHOP (15 HIV+, 16 HIV-; 30 NHL, 1 HL). Five HL patients received first-line ABVD, 1 CLL patient did not require treatment for Rai Stage I disease, and 1 CLL patient received CVP. Patients treated with CHOP received a median 5 cycles (range 1-8). Among 14 of 31 patients receiving <6 CHOP cycles, reasons for stopping were death (n=8), progression (n=1), toxicity (n=3), and social (n=2). Overall survival 6 months after CHOP initiation was 61% (95% CI 38-78%), with no significant differences between HIV+ and HIV- patients (Figure 1). Conclusions. Early experience in Malawi suggests ART has had equalized presentations and outcomes between HIV+ and HIV- lymphoma patients. CHOP can be safe, effective, and feasible in our setting for HIV+ and HIV- patients in the ART era. Among HIV+ patients, ART use, CD4 count, and HIV RNA at lymphoma diagnosis are comparable to contemporary US HIV+ lymphoma cohorts. Outcomes can be further improved through community education, better supportive care, protocol-based treatment, and incorporation of newer agents. Table 1. Characteristics of adult lymphoma patients from June 2013-May 2014 in Lilongwe, Malawi. HIV- (n=21) HIV+ (n=17) P value Age (years), median (range) 45.6 (15.8-77.4) 47.2 (22.4-62.6) 0.51 Male, n (%) 16 (76.2%) 10 (58.8%) 0.31 Body mass index (kg/m2), median (range) 21.3 (16.2-28.0) 20.4 (16.0-31.2) 0.99 Histology 0.21 Aggressive B-cell lymphoma NK/T-cell lymphoma Plasmablastic lymphoma Chronic lymphocytic leukemia Non-Hodgkin lymphoma unspecified Hodgkin lymphoma 9 1 „Ÿ 1 6 4 12 „Ÿ 1 1 1 2 B symptoms, n (%) 18 (85.7%) 12 (70.6%) 0.69 Largest lymph node mass (cm), median (range) 10 (5-20) 6 (2-16) 0.027 Performance status ≥2 10 (47.6%) 4 (23.5%) 0.18 Stage III/IV, n (%) 12 (57.1%) 10 (58.8%) 1.00 White blood cells (103/µL), median (range) 6.8 (2.1-45.7) 5.7 (3.0-17.0) 0.23 Absolute neutrophil count (103/µL), median (range) 2.9 (0.5-29.9) 2.6 (1.0-5.1) 0.19 Hemoglobin (g/dL), median (range) 11.0 (4.4-14.3) 11.6 (5.7-15.1) 0.46 Platelets (103/µL), median (range) 290 (25-725) 190 (101-764) 0.15 Albumin (g/dL), median (range) 3.3 (1.1-4.2) 3.5 (2.1-4.8) 0.78 Lactate dehydrogenase (IU/L), median (range) 321 (134-1,080) 307 (177-2,939) 0.85 Bone marrow involvement, n (%) 2/18 (11.1%) 2/13 (15.4%) 1.00 ≥2 extranodal sites 5 (23.8%) 3 (17.6%) 0.71 Hepatitis B surface antigen positive, n (%) 1/15 (6.7%) 4/15 (26.7%) 0.33 Antiretroviral therapy at enrollment Duration (months), median (range) 14 (82.4%) 22.5 (0.2-98.8) CD4 (cells/µL), median (range) 178 (55-1,288) HIV RNA (log10copies/mL), median (range) 1.8 (ND->7.0) HIV RNA <400 copies/mL, n (%) 9 (52.9%) ND=not detected. Figure 1. Overall survival for 31 adult lymphoma patients treated with CHOP in Lilongwe, Malawi during the 6 months after treatment initiation. Figure 1. Overall survival for 31 adult lymphoma patients treated with CHOP in Lilongwe, Malawi during the 6 months after treatment initiation. Disclosures Shea: CALGB/Alliance: CALGB Board of Directors Other.


Sign in / Sign up

Export Citation Format

Share Document